Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pegylated Lyposomal Doxorubicin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2 |
| Name | Type | Description |
|---|---|---|
| Pegylated Lyposomal Doxorubicin | DRUG | Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy. |
| Cyclophosphamide | DRUG | Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy. |
Inclusion Criteria: * Female, aged \>=18 years. * Subject must have histologic diagnosis of breast carcinoma. * Subject must have documented measurable metastatic breast cancer by appropriate radiologic imaging. * Subject must have previous anthracyclin-based adjuvant regimen and disease-free statu...
Pegylated Lyposomal Doxorubicin is used for the treatment of breast neoplasm, specifically in combination with cyclophosphamide for metastatic breast cancer. It is an investigational small molecule being studied in oncology. The drug is currently in Phase 2 clinical development.
Pegylated Lyposomal Doxorubicin is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating breast cancer.
Pegylated Lyposomal Doxorubicin is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed to evaluate its use in metastatic breast cancer.
Pegylated Lyposomal Doxorubicin has one completed clinical trial, NCT00779129, titled 'A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)'. This Phase 2 trial enrolled 70 female participants aged 18 years and older.
Yes, Pegylated Lyposomal Doxorubicin is also known as Caelyx. The clinical trial NCT00779129 refers to the drug as Caelyx in its title, confirming that these names refer to the same investigational agent.